(redirected from tissue plasminogen activator)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Encyclopedia, Wikipedia.
Related to tissue plasminogen activator: streptokinase
t-PATissue Plasminogen Activator
References in periodicals archive ?
The recombinant vaccine (pEGS/2SS-tPA) was constructed by inserting the sequence of tissue plasminogen activator signal peptide (tPA) into previous somatostatin DNA vaccine (pEGS/2SS) (Cao et al., 2005).
Streamlining the process for intravenous tissue plasminogen activator. J Neurosci Nurs.
Nordoy, "asal plasma concentration of tissue plasminogen activator (tPA) and the adaption to strenuous exercise in familial hypercholesterolaemia (FH)," Blood Coagulation and Fibrinolysis, vol.
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012;307:2600-8.
Keywords: Ischemic stroke Reporting time (RT) Therapeutic window Tissue plasminogen activator (TPA).
Under physiologic conditions, the conversion ofplasminogen to plasmin is regulated by activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), and FXIIa.
Although a medicine called tissue plasminogen activator can break up blood clots in the brain, it must be given soon after the start of symptoms to work, and there are no other clinically effective treatments currently available for this condition.
Tissue plasminogen activator, a protein involved in the breakdown of blood clots, increased (11.6+-5 per cent) immediately after CAP exposure in the olive oil group, and this effect persisted up to 20 hours.
The company will be enrolling around 60 patients in the trial from around 15 sites within and outside the United States with Rutherford Category IIa and IIb acute lower limb ischemia receiving catheter-directed recombinant tissue plasminogen activator and compare a high and low dose of MST-188 against recombinant tissue plasminogen activator alone.
"Our data showed that treatment of acute stroke with AcSDKP alone or in combination with tPA substantially reduced neurovascular damage and improved neurological outcome." Commonly called a "clot-buster," tPA, or tissue plasminogen activator, is the only FDA-approved treatment for acute stroke.
SAN DIEGO - The percentage of patients arriving at hospitals with ischemic stroke who were treated with tissue plasminogen activator within the recommended 60 minutes increased from 30% to 53% on average at 1,030 hospitals engaged in the Target: Stroke program in the past 4 years.